67914-60-7Relevant articles and documents
Design and synthesis of the novel, selective WZ4002 analogue as EGFR-L858R/T790M tyrosine kinase inhibitors for targeted drug therapy in non-small-cell lung cancer (NSCLC)
Ahmad, Iqrar,Belamkar, Sateesh,Kundu, Chanakya Nath,Nayak, Deepika,Patel, Harun,Patil, Chandragauda,Pawara, Rahul,Surana, Sanjay
, (2022/01/12)
To conquer the drug-resistance of first-generation EGFR (epidermal growth factor receptor) kinase inhibitors and second-generation inhibitors’ non-selective toxicities in Non-Small Cell Lung Cancer (NSCLC) patients, a series of WZ4002 derivatives (6–46) were discovered as novel double mutant EGFR-L858R/T790M TK inhibitors. This objective was attained by employing structure-based drug design and traditional optimization strategies based on the WZ4002 scaffold. Among the synthesized compounds, representative compounds 8 and 38 displayed significant anti-proliferative activity on the Gefitinib-resistant cell line NCI-H1975, with an IC50 value of 0.179 μM and 0.173 μM, respectively. Also, these compounds exhibited moderate anti-proliferative activity against the A549 cell, with an IC50 of 0.550 μM and 0.528 μM respectively, suggesting their improved selectivity over the mutant EGFR-L858R/T790M. Excitingly, both these compounds showed significant inhibition of the double mutant EGFR-L858R/T790M TK with an IC50 value of 0.0063 μM and 0.0060 μM, respectively. The IC50 values of both the promising compounds against the HepG2 cell line were more than 1 μM, indicating safety for normal cells. Covalent docking and MD simulation further confirm their irreversible binding mode with the target protein. These results demonstrate that compounds 8 and 38 would be promising lead compound-targeting double mutant EGFR-L858R/T790M TK.
NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE and INFLAMMATORY DISEASES
-
Page/Page column 67, (2008/12/05)
The present invention relates to compounds of formula (I) that are inhibitors of PDElA, a phosphodiesterase that is involved in the modulation of the degradation of cartilage, joint degeneration and diseases involving such degradation and/or inflammation.
Antifungal azole derivatives having a fluorinated vinyl group and process for preparing same
-
, (2008/06/13)
An antifungal compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein: X is CH or N; Y is O, R1and R2are each independently F or Cl; R3is a thiophenyl, naphthyl, or phenyl group, the phenyl group being optionally substituted with one or more substituents selected from the group consisting of C1-4alkyl, C1-4haloalkyl, C1-4alkoxy, methylenedioxy and halogen; and R4is H or trifluoromethyl.